Skip to content
Operating

Operating lease right-of-use asset amortization

Edwards Lifesciences Operating lease right-of-use asset amortization decreased by 1.5% to $6.5M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 6.6%, from $6.1M to $6.5M. Over 4 years (FY 2021 to FY 2025), Operating lease right-of-use asset amortization shows relatively stable performance with a -2.4% CAGR.

Analysis

StatementCash Flow Statement
SectionOperating
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ1 2020
Last reportedQ1 2026May 6, 2026

How to read this metric

An increase suggests a larger footprint of leased assets, while a decrease suggests a reduction in lease obligations.

Detailed definition

This reflects the non-cash amortization of the right-of-use asset created under lease accounting standards. It represent...

Peer comparison

Standard for companies with significant real estate or equipment lease portfolios.

Metric ID: operating_operating_lease_right_of_use_asset_amortizatio_94fda1

Historical Data

20 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$7M$7.1M$7.1M$7.1M$6.8M$6.7M$6.6M$6.8M$6.9M$7M$7.5M$7.7M$7.4M$6.5M$6.2M$6.1M$6.4M$6.8M$6.6M$6.5M
QoQ Change+1.4%+0.0%+0.0%-4.2%-1.5%-1.5%+3.0%+1.5%+1.4%+7.1%+2.7%-3.9%-12.2%-4.6%-1.6%+4.9%+6.3%-2.9%-1.5%
YoY Change-2.9%-5.6%-7.0%-4.2%+1.5%+4.5%+13.6%+13.2%+7.2%-7.1%-17.3%-20.8%-13.5%+4.6%+6.5%+6.6%
Range$6.1M$7.7M
CAGR-1.5%
Avg YoY Growth-1.3%
Median YoY Growth-0.7%
Current Streak2 quarters decline

Frequently Asked Questions

What is Edwards Lifesciences's operating lease right-of-use asset amortization?
Edwards Lifesciences (EW) reported operating lease right-of-use asset amortization of $6.5M in Q1 2026.
How has Edwards Lifesciences's operating lease right-of-use asset amortization changed year-over-year?
Edwards Lifesciences's operating lease right-of-use asset amortization increased by 6.6% year-over-year, from $6.1M to $6.5M.
What is the long-term trend for Edwards Lifesciences's operating lease right-of-use asset amortization?
Over 4 years (2021 to 2025), Edwards Lifesciences's operating lease right-of-use asset amortization has grown at a -2.4% compound annual growth rate (CAGR), from $28.5M to $25.9M.
What does operating lease right-of-use asset amortization mean?
The non-cash expense for the usage of leased assets.